PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4548652

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS	08/11/2017

RECEIVING PARTY DATA

Name:	BIOVENTURES, LLC
Street Address:	4301 W. MARKHAM ST., #831
City:	LITTLE ROCK
State/Country:	ARKANSAS
Postal Code:	72205-7199

PROPERTY NUMBERS Total: 16

Property Type	Number
Patent Number:	7094886
Patent Number:	7696150
Patent Number:	8501702
Patent Number:	7668659
Patent Number:	7894992
Patent Number:	7308364
Application Number:	12001110
Patent Number:	7983850
Patent Number:	7935679
Patent Number:	8954283
Patent Number:	9574238
Patent Number:	9714451
Application Number:	15436230
Application Number:	14892555
Patent Number:	8843320
Patent Number:	9650677

CORRESPONDENCE DATA

Fax Number: (202)672-5399

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone:	(202) 672-5300
Email:	kstrawderman@foley.com, ipdocketing@foley.com
Correspondent Name:	KRISTEL SCHORR
Address Line 1:	FOLEY & LARDNER LLP
Address Line 2:	3000 K STREET N.W., SUITE 600
Address Line 4:	WASHINGTON, D.C. 20007

ATTORNEY DOCKET NUMBER:	034827-0100 (16)
NAME OF SUBMITTER:	KRISTEL SCHORR
SIGNATURE:	/Kristel Schorr/
DATE SIGNED:	08/14/2017

Total Attachments: 9
source=Assignment#page1.tif
source=Assignment#page2.tif
source=Assignment#page3.tif
source=Assignment#page4.tif
source=Assignment#page5.tif
source=Assignment#page6.tif
source=Assignment#page7.tif
source=Assignment#page8.tif
source=Assignment#page9.tif

PATENT ASSIGNMENT

WHEREAS the **Board of Trustees of the University of Arkansas**, a University, with offices at 2404 North University Avenue, Little Rock, Arkansas 72207 (hereinafter "Assignor") is the assignee of the invention rights in the United States of America and its territories and possessions thereof and all foreign countries to the patent applications on the attached Schedule A;

WHEREAS **BioVentures, LLC**, an Arkansas limited liability company, with offices at 4301 W. Markham St., #831, Little Rock, Arkansas 72205-7199 (hereinafter "Assignee") is desirous of acquiring all right, title and interest for the United States of America, its territories and possessions thereof and all foreign countries in and to the invention(s) relating thereto, identified on the attached Schedule A,

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by Assignor, Assignor hereby assigns to Assignee the entire and exclusive right, title and interest in and to said inventions for the United States of America, and in and to said worldwide patent applications listed on the attached Schedule A, including any and all divisional, continuation, continuation-in-part, reissues or extensions thereof, to be held and enjoyed by Assignee for its own use as fully and entirely as the same would have been held and enjoyed by Assignor had this assignment not been made; the Commissioner of Patents and Trademarks of the United States of America is hereby authorized to transfer the portion of the title indicated to said application to said Assignee in accordance herewith; this assignment being under covenant, not only that full power to make the same is had by the Assignor, but also that such assigned rights are not encumbered by any grant, license, or other right theretofore given; Assignor hereby undertakes to execute and deliver to Assignee upon request all lawful documents which may be requested by Assignee, and to furnish Assignee with all facts relating to said invention as may be requested.

The undersigned hereby grant the firm of FOLEY & LARDNER LLP, the power to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

***Assignor*: Board of Trustees of the University of Arkansas**

Date: 8-11-17

By: _____

Name: Stephanie Gardner

Title: Interim Chancellor

ACKNOWLEDGMENT

STATE OF Arkansas)

) SS.

COUNTY OF Pulaski)

On this 11 day of August, 2017, before me, a Notary Public, personally appeared Stephanie Gardner to me to be the person described, in and who executed, the foregoing assignment and acknowledged that he/she executed said instrument as his/her free act and deed.

In Testimony Whereof, I have hereunto set my hand and affixed my official seal the day and year first above written.

_____
Notary Public

My Commission Expires:

6-7-26 [SEAL]

TARA L AUSTIN
MY COMMISSION EXPIRES
06-07-2026
NOTARY
PUBLIC
COMM. #12348549
PULASKI COUNTY - ARKANSAS

4813-7082-6572.1

Assignee: **BioVentures, LLC**

Date: August 11, 2017

By: Nancy M. Gray

Name: Nancy M. Gray

Title: President

ACKNOWLEDGMENT

STATE OF Arkansas)

) SS.

COUNTY OF Pulaski)

On this 11 day of August, 2017, before me, a Notary Public, personally appeared Nancy M. Gray to me to be the person described, in and who executed, the foregoing assignment and acknowledged that he/she executed said instrument as his/her free act and deed.

In Testimony Whereof, I have hereunto set my hand and affixed my official seal the day and year first above written.

Alison M. Gill

Notary Public

My Commission Expires:

4/15/2020 [SEAL]

ALISON M. GILL
MY COMMISSION # 12376156
EXPIRES: April 15, 2020
Pulaski County

4813-7082-6572.1

SCHEDULE A

Country	Application No.	Application Date	Patent No.	Grant Date	Title
U.S.	09/778971	2/2/2001	7094886	8/22/2006	EVI27 GENE SEQUENCE AND PROTEIN ENCODED THEREBY
U.S.	11/128403	5/12/2005	7696150	4/13/2010	MODULATION OF THE ACTIVITY OF AN INTERLEUKIN 17 RECEPTOR- RELATED PROTEIN, EVI27, AND USES THEREOF
U.S.	11/999301	12/4/2007	8501702	8/6/2013	OVEREXPRESSION OF WNT LIGANDS AND TREATMENT OF LYTIC BONE DISEASES
U.S.	10/289746	11/7/2002	7668659	2/23/2010	DIAGNOSIS AND CLASSIFICATION OF MULTIPLE MYELOMA
U.S.	10/409004	4/8/2003	7894992	2/22/2011	DIAGNOSIS AND CLASSIFICATION OF MULTIPLE MYELOMA
U.S.	10/454263	6/4/2003	7308364	12/11/2007	DIAGNOSIS OF MULTIPLE MYELOMA BASED ON GENE EXPRESSION PROFILING
U.S.	12/001110	12/10/2007			Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
U.S.	12/012302	2/1/2008	7983850	7/19/2011	DIAGNOSIS, PROGNOSIS, IDENTIFICATION, AND CLASSIFICATION OF MULTIPLE MYELOMA BASED ON GENE EXPRESSION PROFILING
U.S.	11/110209	4/20/2005	7935679	5/3/2011	A GENE EXPRESSION PROFILING BASED IDENTIFICATION OF CKS1B AS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA

U.S.	12/587383	10/6/2009	8954283	2/10/2015	DIAGNOSIS, PROGNOSIS AND IDENTIFICATION OF POTENTIAL THERAPEUTIC TARGETS OF MULTIPLE MYELOMA BASED ON GENE EXPRESSION PROFILING
U.S.	13/900393	5/22/2013	9574238	2/21/2017	DIAGNOSIS, PROGNOSIS AND IDENTIFICATION OF POTENTIAL THERAPEUTIC TARGETS OF MULTIPLE MYELOMA BASED ON GENE EXPRESSION PROFILING
U.S.	14/039728	9/27/2013	9714451	7/25/2017	DIAGNOSIS, PROGNOSIS AND IDENTIFICATION OF POTENTIAL THERAPEUTIC TARGETS OF MULTIPLE MYELOMA BASED ON GENE EXPRESSION PROFILING
U.S.	15/436230	2/17/2017			DIAGNOSIS, PROGNOSIS AND IDENTIFICATION OF POTENTIAL THERAPEUTIC TARGETS OF MULTIPLE MYELOMA BASED ON GENE EXPRESSION PROFILING
P.C.T.	PCT/US2005/031038	8/31/2005			DIAGNOSIS, PROGNOSIS AND IDENTIFICATION OF POTENTIAL THERAPEUTIC TARGETS OF MULTIPLE MYELOMA BASED ON GENE EXPRESSION PROFILING
P.C.T.	PCT/US2010/002697	10/6/2010			DIAGNOSIS, PROGNOSIS AND IDENTIFICATION OF POTENTIAL

					THERAPEUTIC TARGETS OF MULTIPLE MYELOMA BASED ON GENE EXPRESSION PROFILING
U.S.	60/857456	11/7/2006			GENE EXPRESSION PROFILING BASED IDENTIFICATION OF GENOMIC SIGNATURE OF MULTIPLE MYELOMA TO PREDICT DISEASE PROGRESSION
P.C.T.	PCT/US2007/023404	11/7/2007			GENE EXPRESSION PROFILING BASED IDENTIFICATION OF GENOMIC SIGNATURE OF HIGH-RISK MULTIPLE MYELOMA AND USES THEREOF
European Patent Office	07861764.4	11/7/2007	2087139	1/4/2017	GENE EXPRESSION PROFILING BASED IDENTIFICATION OF GENOMIC SIGNATURE OF HIGH-RISK MULTIPLE MYELOMA AND USES THEREOF
Switzerland	07861764.4	11/7/2007	2087139	1/4/2017	GENE EXPRESSION PROFILING BASED IDENTIFICATION OF GENOMIC SIGNATURE OF HIGH-RISK MULTIPLE MYELOMA AND USES THEREOF
Germany	07861764.4	11/7/2007	2087139	1/4/2017	GENE EXPRESSION PROFILING BASED IDENTIFICATION OF GENOMIC SIGNATURE OF HIGH-RISK MULTIPLE MYELOMA AND USES THEREOF
Denmark	07861764.4	11/7/2007	2087139	1/4/2017	GENE EXPRESSION PROFILING BASED IDENTIFICATION OF GENOMIC SIGNATURE OF HIGH-

					RISK MULTIPLE MYELOMA AND USES THEREOF
Spain	07861764.4	11/7/2007	2087139	1/4/2017	GENE EXPRESSION PROFILING BASED IDENTIFICATION OF GENOMIC SIGNATURE OF HIGH-RISK MULTIPLE MYELOMA AND USES THEREOF
France	07861764.4	11/7/2007	2087139	1/4/2017	GENE EXPRESSION PROFILING BASED IDENTIFICATION OF GENOMIC SIGNATURE OF HIGH-RISK MULTIPLE MYELOMA AND USES THEREOF
United Kingdom	07861764.4	11/7/2007	2087139	1/4/2017	GENE EXPRESSION PROFILING BASED IDENTIFICATION OF GENOMIC SIGNATURE OF HIGH-RISK MULTIPLE MYELOMA AND USES THEREOF
Italy	07861764.4	11/7/2007	2087139	1/4/2017	GENE EXPRESSION PROFILING BASED IDENTIFICATION OF GENOMIC SIGNATURE OF HIGH-RISK MULTIPLE MYELOMA AND USES THEREOF
Netherlands	07861764.4	11/7/2007	2087139	1/4/2017	GENE EXPRESSION PROFILING BASED IDENTIFICATION OF GENOMIC SIGNATURE OF HIGH-RISK MULTIPLE MYELOMA AND USES THEREOF
Sweden	07861764.4	11/7/2007	2087139	1/4/2017	GENE EXPRESSION PROFILING BASED IDENTIFICATION OF GENOMIC SIGNATURE OF HIGH-RISK MULTIPLE MYELOMA AND USES THEREOF

Japan	2009536276	11/7/2007	5531360	5/9/2014	GENE EXPRESSION PROFILING BASED IDENTIFICATION OF GENOMIC SIGNATURE OF HIGH-RISK MULTIPLE MYELOMA AND USES THEREOF
U.S.	61/825396	5/20/2013			GEP5 MODEL FOR MULTIPLE MYELOMA
P.C.T.	PCT/US2014/038626	5/19/2014			GEP5 MODEL FOR MULTIPLE MYELOMA
U.S.	14/892555	5/19/2014			GEP5 MODEL FOR MULTIPLE MYELOMA
Canada	2912312	5/19/2014			GEP5 MODEL FOR MULTIPLE MYELOMA
European Patent Office	14729567.9	5/19/2014	2999796	3/30/2016	GEP5 MODEL FOR MULTIPLE MYELOMA
Japan	2016-514991	5/19/2014			GEP5 MODEL FOR MULTIPLE MYELOMA
European Patent Office	12150351.0	5/20/2005	2537942	9/23/2015	USE OF GENE EXPRESSION PROFILING TO PREDICT SURVIVAL IN CANCER PATIENT
Switzerland	12150351.0	5/20/2005	2537942	9/23/2015	USE OF GENE EXPRESSION PROFILING TO PREDICT SURVIVAL IN CANCER PATIENT
Germany	12150351.0	5/20/2005	2537942	9/23/2015	USE OF GENE EXPRESSION PROFILING TO PREDICT SURVIVAL IN CANCER PATIENT
Denmark	12150351.0	5/20/2005	2537942	9/23/2015	USE OF GENE EXPRESSION PROFILING TO PREDICT SURVIVAL IN CANCER PATIENT
Spain	12150351.0	5/20/2005	2537942	9/23/2015	USE OF GENE EXPRESSION PROFILING TO PREDICT SURVIVAL IN CANCER PATIENT

France	12150351.0	5/20/2005	2537942	9/23/2015	USE OF GENE EXPRESSION PROFILING TO PREDICT SURVIVAL IN CANCER PATIENT
United Kingdom	12150351.0	5/20/2005	2537942	9/23/2015	USE OF GENE EXPRESSION PROFILING TO PREDICT SURVIVAL IN CANCER PATIENT
Italy	12150351.0	5/20/2005	2537942	9/23/2015	USE OF GENE EXPRESSION PROFILING TO PREDICT SURVIVAL IN CANCER PATIENT
Netherlands	12150351.0	5/20/2005	2537942	9/23/2015	USE OF GENE EXPRESSION PROFILING TO PREDICT SURVIVAL IN CANCER PATIENT
Sweden	12150351.0	5/20/2005	2537942	9/23/2015	USE OF GENE EXPRESSION PROFILING TO PREDICT SURVIVAL IN CANCER PATIENT
Canada	2567350	5/20/2005			USE OF GENE EXPRESSION PROFILING TO PREDICT SURVIVAL IN CANCER PATIENT
U.S.	11/133937	5/20/2005	8843320	9/23/2014	USE OF GENE EXPRESSION PROFILING TO PREDICT SURVIVAL IN CANCER PATIENT
U.S.	13/899196	5/21/2013	9650677	5/16/2017	USE OF GENE EXPRESSION PROFILING TO PREDICT SURVIVAL IN CANCER PATIENT